Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Frontiers in Immunology|May 2, 2022
A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid TumorsJames J Harding, Ignacio Garrido-Laguna, Xiaoying Chen, et al.
Clinical Pharmacology and Therapeutics|June 7, 2024
Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno-Safety Technical Committee (ITC)Mineo Matsumoto, Joseph Ryan Polli, Suresh K Swaminathan, et al.
Cancer Immunology, Immunotherapy : CII|March 13, 2012
Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activityTimothy S Fisher, Cris Kamperschroer, Theodore Oliphant, et al.
Immunological Reviews|July 11, 2006
CD4+ T-cell memory: generation and multi-faceted roles for CD4+ T cells in protective immunity to influenzaSusan L Swain, Javed N Agrewala, Deborah M Brown, et al.
Regulatory Toxicology and Pharmacology : RTP|February 1, 2026
FIH Dose Selection Beyond MABEL: Optimizing Phase 1 clinical trial Starting Dose Whilst Protecting Patient SafetyMineo Matsumoto, J Ryan Polli, Suresh Swaminathan, et al.
Cytotherapy|August 23, 2025
Cytokine release syndrome risk model with T-cell engaging therapiesPénélope Lafeuille, William A Blumentals, Claire Brulle-Wohlhueter, et al.
Molecular Cancer Therapeutics|August 28, 2020
Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 AntibodyAmir A Al-Khami, Sawsan Youssef, Yasmina Abdiche, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2020
A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal CancersDivya Mathur, Adam R Root, Bozena Bugaj-Gaweda, et al.
Molecular Cancer Therapeutics|August 23, 2019
Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple MyelomaSiler H Panowski, Tracy C Kuo, Yi Zhang, et al.
Pageof 3